Children with COVID-19 to be enrolled in remdesivir clinical trial

Remdesivir has been shown to help adults with the coronavirus recover.

A vial of remdesivir at a Gilead manufacturing site in the United States
A vial of remdesivir at a Gilead manufacturing site in the United States.Gilead Sciences / via AP file

Breaking News Emails

Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings.


Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing its experimental drug, remdesivir.

The trial will assess the effectiveness and safety of the drug in the patients, which would include newborns to adolescents, across more than 30 sites in the United States and Europe, the company said.

Full coverage of the coronavirus outbreak

Gilead’s remdesivir, which has been at the forefront in the fight against the virus and has been given emergency use authorization in some countries, could be helpful in some patients after data showed it could shorten the time taken to recover from the disease.

The company is already running a late-stage study testing the drug in 6,000 patients with severe COVID-19.

Football news:

Hazard will miss the match with athletic
Juventus are Interested in Jacko
Micah Richards: Arsenal need to keep the Forward. It can attract other top players
York on Keane's criticism of De Gea and Maguire: Roy himself was not perfect when he played. He should be more restrained
Setien on Griezmann: When he plays, I am asked about Fathi, and Vice versa. Antoine is important to Barca
Setien on the situation with Messi: I haven't heard anything from him. Everything else is speculation
Sane did not pose in the number 10 shirt out of respect for Coutinho